Valuation: TScan Therapeutics, Inc.

Market Cap 64.05M 56.06M 51.75M 48.27M 90.96M 6.06B 92.58M 621M 241M 2.99B 241M 235M 10.41B P/E 2026 *
-1.12x
P/E 2027 * -1.06x
Enterprise Value -34.82M -30.48M -28.13M -26.24M -49.44M -3.29B -50.33M -337M -131M -1.62B -131M -128M -5.66B EV / Sales 2026 *
-4.61x
EV / Sales 2027 * -1.37x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
06-22 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
06-22 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
06-03 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
05-06 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-02 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
03-04 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-26 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
02-26 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
12-19 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
12-07 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
11-14 Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight MT
11-12 TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-12 TScan Therapeutics Q3 revenue jumps RE
1 day+0.27%
1 week+6.42%
1 month-9.25%
3 months-2.96%
6 months-1.99%
Current year-1.99%
1 week 0.83
Extreme 0.8251
1.07
1 month 0.83
Extreme 0.8251
1.07
Current year 0.83
Extreme 0.8251
1.47
1 year 0.83
Extreme 0.8251
2.57
3 years 0.83
Extreme 0.8251
9.69
5 years 0.83
Extreme 0.8251
14.71
10 years 0.83
Extreme 0.8251
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Director of Finance/CFO 57 29/01/2024
Chief Tech/Sci/R&D Officer 50 08/04/2024
Director TitleAgeSince
Director/Board Member 68 23/03/2021
Director/Board Member 56 24/05/2023
Chairman 55 12/06/2024
Date Insider Type Main position Quantity % Market Cap.
05-20Free

Director

67,000 0.1200%
05-20
Baker Bros. Advisors LP
FreeCompany 134,000 0.2400%
05-20Free

Director

67,000 0.1200%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%+6.42%-32.41%-60.80% 63.88M
+3.31%-0.20%+72.71%+128.31% 55.78B
-1.32%+17.12%+79.02%+99.82% 55.66B
-1.28%+2.68%-12.60%-13.79% 23.84B
+1.79%+4.38%+5.94%+405.31% 22.7B
-1.93%+11.11%+34.89%-7.86% 18.5B
+4.45%+5.06%+36.50%-30.43% 16.12B
+0.24%+5.98%+23.45%+184.72% 13.64B
+0.14%+9.60%+33.31% - 12.95B
+1.83%+4.58%+77.42%+132.45% 12.16B
Average +0.75%+6.13%+31.82%+93.08% 23.14B
Weighted average by Cap. +0.80%+5.21%+48.46%+114.79%

Financials

2026 *2027 *
Net sales 7.56M 6.62M 6.11M 5.7M 10.73M 715M 10.92M 73.25M 28.44M 353M 28.39M 27.76M 1.23B 7.81M 6.83M 6.31M 5.88M 11.09M 738M 11.29M 75.67M 29.38M 364M 29.33M 28.68M 1.27B
Net income -115M -101M -92.98M -86.73M -163M -10.88B -166M -1.12B -433M -5.37B -432M -423M -18.7B -125M -109M -101M -94.07M -177M -11.8B -180M -1.21B -470M -5.82B -469M -458M -20.29B
Net Debt -98.87M -86.54M -79.88M -74.52M -140M -9.35B -143M -958M -372M -4.61B -371M -363M -16.07B -74.76M -65.43M -60.4M -56.34M -106M -7.07B -108M -725M -281M -3.49B -281M -275M -12.15B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
30/06/26 $0.9801 +0.27% 1,044,487
29/06/26 $0.9775 +0.90% 1,263,139
26/06/26 $0.9688 +15.33% 713,271
25/06/26 $0.8400 -4.64% 647,370
24/06/26 $0.8809 -4.35% 452,195
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.9801USD
Average target price
6.000USD
Spread / Average Target
+512.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock